Identification of new therapies for leiomyomas: What in vitro studies can tell us

Clinical Obstetrics and Gynecology

Volumn 44, Issue 2, 2001, Pages 327-334

  Nowak, Romana A ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR; GONADORELIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; PLATELET DERIVED GROWTH FACTOR; RG 13577; SOMATOMEDIN; STEROID HORMONE; STEROID HORMONE ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; IN VITRO STUDY; KELOID; LEIOMYOMA; LUNG FIBROSIS; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; UTERUS MYOMA; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INDUCING AGENTS; FEMALE; FIBROSIS; HUMANS; LEIOMYOMA; SOMATOMEDINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 0035037694     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200106000-00019     Document Type: Review

References (62)

1. Uterine leiomyomata: Etiology, symptomatology and management
2. Uterine fibroids: A clinical review
3. Uterine leiomyomas: The somatic mutation theory
4. Hysterectomy in the United States, 1988-1990
5. Steroidal treatment of leiomyomas: Preoperative and long term medical therapy
6. Unconjugated steroids in leiomyomas and tumor-bearing myometrium
7. Mitotic activity in uterine leiomyomas during the menstrual cycle
8. Progesterone: A critical role in the pathogenesis of uterine leiomyomas
9. Estrogen receptor gene expression in human uterine leiomyomas
10. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium
11. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/ paracrine mechanism
12. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma
13. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat
14. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone
15. Histological and biochemical studies of collagen in human uterine leiomyomas
16. Relative overexpression of collagen type I and collagen type III mRNAs by uterine leiomyomas during the proliferative phase of the menstrual cycle
17. The transforming growth factor-β family
18. The cell biology of transforming growth factor-β
19. TGFβ signaling: Receptors, transducers, and MAD proteins
20. Regulation by estrogen (E) of the transforming growth factor-β (TGF-β) system in uterine leiomyomas
21. Transforming growth factor-beta 3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation
22. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-β3 (TGF-β3) and altered responses to the anti-proliferative effects of TGF-βs
23. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions
24. Regional variability in the time course of TGF-β1 expression, cellular proliferation and extracellular matrix expansion following arterial injury
25. Transforming growth factor beta 1 expression and effect in aortic smooth muscle cells from spontaneously hypertensive rats
26. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions
27. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids
28. Keloid-derived fibroblasts are refractory to fasmediated apoptosis and neutralization of autocrine transforming growth factor-beta 1 can abrogate this resistance
29. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy
30. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells
31. Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleiomycin-induced pulmonary fibrosis in rats
32. Treatment of idiopathic pulmonary fibrosis (IPF) with a new anti-fibrotic drug- pirfenidone
33. Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production
34. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone
35. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
36. Novel therapeutic strategies for leiomyomas: Targeting growth factors and their receptors
37. Smooth muscle cell and endothelial cell growth factors
38. The blood supply of uterine myomata
39. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium
40. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomas
41. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium
42. Presence of epidermal growth factor, platelet derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: Their action in smooth muscle cells in vitro
43. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells
44. An endothelial growth factor involved in rat renal development
45. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of α-smooth muscle actin, calponin h1 and p27
46. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds
47. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound
48. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors
49. Interferon-alfa-2a therapy for life-threatening hemangiomas of infancy
50. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomasa
51. Interferon-α is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells
52. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon-alpha treatment for hepatitis
53. Elevated level of basic fibroblast growth factor in leiomyoma-related abnormal uterine bleeding and its reversal by interferon-alpha
54. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues
55. Uterine insulin-like growth factor-I receptors: Regulation by estrogen and variations throughout the estrous cycle
56. Insulin-like growth factor-I promotes leiomyoma cell growth in vitro
57. Insulin-like growth factor gene expression in human smooth muscle tumors
58. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium
59. Gene expression and tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal conditions
60. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata
61. Overexpression of insulin-like growth factor-I (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts
62. Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloids